Literature DB >> 12875284

Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico.

Elvia Diaz1, Jaime Mondragon, Enrique Ramirez, Rosamaria Bernal.   

Abstract

The purpose of this study was to evaluate the efficacy and the tolerance of nitazoxanide in children as a single broad-spectrum antiparasitic agent in the treatment of mixed parasite infections with both intestinal protozoa and helminths. Two hundred seventy-two children (age range = 2-14 years) participated in this study. We systematically surveyed every household head using questionnaires designed to obtain information about household socioeconomic status and hygiene. Parasitic infections were confirmed by three stool examinations using direct smear, Ferreira concentration, and cold acid-fast Kinyoun staining methods. One hundred twenty-one (44%) children tested positive for protozoa such as Giardia lamblia (18%), Entamoeba histolytica/E. dispar (10%), Blastocystis hominis (7%), Cryptosporidium parvum (4%), and Cyclospora cayetanensis (3%), and helminths such as Hymenolepis nana (10%), Trichuris trichiura (6%), and Ascaris lumbricoides (6%). There were also two cases of infection with Enterobius vermicularis. After a complete physical examination was performed, 121 patients received treatment with nitazoxanide. Overall, 84% of the protozoa and 95% of the helminths were completely eliminated from the patients. Nitazoxanide was very well tolerated, with no serious adverse effects reported.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875284

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  40 in total

1.  Cyclosporiasis: an update.

Authors:  Cirle Alcantara Warren
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

2.  Cyclospora cayetanensis in a pediatric hospital in Morelia, México.

Authors:  Guadalupe E Orozco-Mosqueda; Orlando A Martínez-Loya; Ynes R Ortega
Journal:  Am J Trop Med Hyg       Date:  2014-06-23       Impact factor: 2.345

Review 3.  Susceptibility Testing of Medically Important Parasites.

Authors:  Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

4.  Development of metronidazole-resistant lines of Blastocystis sp.

Authors:  L A Dunn; K S W Tan; P Vanelle; T Juspin; M D Crozet; T Terme; P Upcroft; J A Upcroft
Journal:  Parasitol Res       Date:  2012-02-24       Impact factor: 2.289

5.  Nitazoxanide : A Broad Spectrum Antimicrobial.

Authors:  Nishith Singh; S Narayan
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Nitazoxanide: nematicidal mode of action and drug combination studies.

Authors:  Vishal S Somvanshi; Brian L Ellis; Yan Hu; Raffi V Aroian
Journal:  Mol Biochem Parasitol       Date:  2014-01-08       Impact factor: 1.759

Review 7.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

8.  Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model.

Authors:  Lourrany B Costa; Eric A JohnBull; Jordan T Reeves; Jesus Emmanuel Sevilleja; Rosemayre S Freire; Paul S Hoffman; Aldo A M Lima; Reinaldo B Oriá; James K Roche; Richard L Guerrant; Cirle Alcantara Warren
Journal:  J Parasitol       Date:  2011-06-28       Impact factor: 1.276

9.  The association of Blastocystis hominis and Endolimax nana with diarrheal stools in Zambian school-age children.

Authors:  Thaddeus K Graczyk; Clive K Shiff; Leena Tamang; Fair Munsaka; Anna M Beitin; William J Moss
Journal:  Parasitol Res       Date:  2005-10-25       Impact factor: 2.289

Review 10.  New insights on classification, identification, and clinical relevance of Blastocystis spp.

Authors:  Kevin S W Tan
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.